DUBLIN, August 12, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Idiopathic Pulmonary Fibrosis: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.
The FDA simultaneously approved both Esbriet and Ofev in October 2014, making them the first treatments specifically approved for IPF in the US.
This report addresses the following questions:
- How large is the IPF patient population and how many patients are drug-treated across the various severities?
- What clinical differentiation exists between the two approved products and how does this sway physician behavior?
- What degree of uptake are Esbriet and Ofev experiencing shortly after their launch?
- How will the sales trajectories of the two products differ?
- Now that there are specifically approved treatment options, how will clinical trial design and product positioning for future products change?
Key Topics Covered:
FORECAST: IDIOPATHIC PULMONARY FIBROSIS
- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Esbriet (pirfenidone)
- Ofev (nintedanib)
- Primary Research Methodology
TREATMENT: IDIOPATHIC PULMONARY FIBROSIS
- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis,
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
EPIDEMIOLOGY: IDIOPATHIC PULMONARY FIBROSIS
- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
MARKETED DRUGS: IDIOPATHIC PULMONARY FIBROSIS
- Executive Summary
- Product Overview
- Product profile: Esbriet
- Product profile: Ofev
PIPELINE: IDIOPATHIC PULMONARY FIBROSIS
- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Clinical Trial Design
- Product profile (late stage): FG-30
- Product profile (late stage): PRM-151
For more information about this report visit http://www.researchandmarkets.com/research/wszzt8/idiopathic
Related Topics: Respiratory Drugs
Media Contact:
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article